Breast CancerNCT01286233
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
An observational study of Breast Cancer and Depression, run by NSABP Foundation Inc at 256 sites in 2 countries.
Trial summary
RATIONALE: Studying samples of blood in the laboratory from patients with breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue. Read more about this study
- Who is it for?
- Ages 18 to 74 years, women only
- Conditions the study is for
- Breast Cancer, Depression, Fatigue
- What is being tested?
- Metformin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 394 participants
- Where
- 256 sitesin 2 countries
- Study dates
- Jul 2011to Sep 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with breast cancer who have been diagnosed and have undergone definitive surgical treatment for invasive breast cancer within the previous 12 months and who are eligible for randomization to NCIC MA.32.
Who may be able to join
- The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the MA.32.F Study before being enrolled.
- The patient must be female.
- The patient must reside in the United States or Canada.
- The patient must be English-speaking.
- The patient must be eligible for randomization in the MA.32 treatment trial. (Participation in the MA.32 QOL study is permitted but not required.)
- The patient must not have started taking MA.32 study therapy.
- The patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in MA.32.F.
Who cannot join
- MA.32 study therapy has been initiated.
- Currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting MA.32 study therapy.
Trial locations and contacts
256 sites in 2 countries.
256 sites in 2 countries
United States252 sites
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Kaiser Permanente Medical Center - Anaheim/Orange County
Anaheim, California, 92807
AnMed Cancer Center
Anderson, South Carolina, 29621
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
Kaiser Permanente Medical Center - Baldwin Park
Baldwin Park, California, 91706
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Overlake Cancer Center at Overlake Hospital Medical Center
Bellevue, Washington, 98004
Kaiser Permanente Medical Center - Bellflower
Bellflower, California, 90706
Mountainview Medical
Berlin Corners, Vermont, 05602
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
St. Joseph Medical Center
Bloomington, Illinois, 61701
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Graham Hospital
Canton, Illinois, 61520
Illinois CancerCare - Canton
Canton, Illinois, 61520
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Resurrection Medical Center
Chicago, Illinois, 60631
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Evanston Hospital
Evanston, Illinois, 60201-1781
Providence Regional Cancer Partnership
Everett, Washington, 98201
Dakota Cancer Institute at Dakota Clinic - South University
Fargo, North Dakota, 58103
St. Francis Hospital
Federal Way, Washington, 98003
McLeod Regional Medical Center
Florence, South Carolina, 29501
Kaiser Permanente Medical Center - Fontana
Fontana, California, 92335
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, 21701
Kaiser Permanente - Fremont
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Kaiser Permanente Medical Center - Harbor City
Harbor City, California, 90710
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Illinois CancerCare - Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
High Point Regional Hospital
High Point, North Carolina, 27261
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Kaiser Permanente - Irvine
Irvine, California, 92618
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Monter Cancer Center of the North Shore-LIJ Health System
Lake Success, New York, 11042
Doctor's Hospital of Laredo
Laredo, Texas, 78045
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
St. Joseph Regional Medical Center
Lewiston, Idaho, 83501
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California, 90027
Kaiser Foundation Hospital - West Los Angeles
Los Angeles, California, 90034
Lowell General Hospital
Lowell, Massachusetts, 01854
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
McDonough District Hospital
Macomb, Illinois, 61455
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, 11030
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology - Maplewood
Maplewood, Minnesota, 55109
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Marlton, New Jersey, 08053
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Cancer Center of Kansas, PA - McPherson
McPherson, Kansas, 67460
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Trinity CancerCare Center
Minot, North Dakota, 58701
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Illinois CancerCare - Monmouth
Monmouth, Illinois, 61462
OSF Holy Family Medical Center
Monmouth, Illinois, 61462
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Mercy General Health Partners
Muskegon, Michigan, 49444
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
New Ulm Medical Center
New Ulm, Minnesota, 56073
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, 10032
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Illinois CancerCare - Community Cancer Center
Normal, Illinois, 61761
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Estabrook Cancer Center
Omaha, Nebraska, 68114
Immanuel Medical Center
Omaha, Nebraska, 68122
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
Ontario, California, 91761
Willamette Falls Hospital
Oregon City, Oregon, 97045
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Kaiser Permanente Medical Group
Panorama City, California, 91402
Cancer Center of Paoli Memorial Hospital
Paoli, Pennsylvania, 19301-1792
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Illinois CancerCare - Pekin
Pekin, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare - Peru
Peru, Illinois, 61354
Illinois Valley Community Hospital
Peru, Illinois, 61354
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
Cancer Center at Phoenixville Hospital
Phoenixville, Pennsylvania, 19460
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
Pinehurst, North Carolina, 28374
UPMC Cancer Centers
Pittsburgh, Pennsylvania, 15232
Michiana Hematology Oncology PC - Plymouth
Plymouth, Indiana, 46563
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Kaiser Permanente Health Care - Portland
Portland, Oregon, 97227
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Illinois CancerCare - Princeton
Princeton, Illinois, 61356
Perry Memorial Hospital
Princeton, Illinois, 61356
Good Samaritan Cancer Center
Puyallup, Washington, 98372
Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, 27607
Kaiser Permanente Medical Center - Redwood City
Redwood City, California, 94063
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Kaiser Permanente Medical Center - Richmond
Richmond, California, 94801
Kaiser Permanente Medical Center - Riverside
Riverside, California, 92505
Humphrey Cancer Center at North Memorial Outpatient Center
Robbinsdale, Minnesota, 55422-2900
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
South Sacramento Kaiser-Permanente Medical Center
Sacramento, California, 95823
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Lakeside Cancer Specialists, PLLC
Saint Joseph, Michigan, 49085
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Cancer Center
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Kaiser Permanente Medical Office -Vandever Medical Office
San Diego, California, 92108
Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego
San Diego, California, 92120
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California, 94115
Kaiser Permanente Medical Center - Santa Teresa
San Jose, California, 95119
Kaiser Permanente Health Care
San Marcos, California, 92078
Kaiser Foundation Hospital - San Rafael
San Rafael, California, 94903
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
Santa Clara, California, 95051
Kaiser Permanente Medical Center - Santa Rosa
Santa Rosa, California, 95403
St. Francis Cancer Center at St. Francis Medical Center
Shakopee, Minnesota, 55379
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51102
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Kaiser Permanente Medical Center - South San Francisco
South San Francisco, California, 94080
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Illinois CancerCare - Spring Valley
Spring Valley, Illinois, 61362
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
Midwest Hematology Oncology Group, Incorporated
St Louis, Missouri, 63109
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Lakeview Hospital
Stillwater, Minnesota, 55082
Kaiser Permanente Medical Facility - Stockton
Stockton, California, 95210
Stony Brook University Cancer Center
Stony Brook, New York, 11794-9446
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Franciscan Cancer Center at St. Joseph Medical Center
Tacoma, Washington, 98405-3004
Allenmore Hospital
Tacoma, Washington, 98405
CCOP - Northwest
Tacoma, Washington, 98405
MultiCare Regional Cancer Center at Tacoma General Hospital
Tacoma, Washington, 98405
St. Clare Hospital
Tacoma, Washington, 98499
Munson Medical Center
Traverse City, Michigan, 49684
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Kaiser Permanente Medical Center - Vacaville
Vacaville, California, 95688
Kaiser Permanente Medical Center - Vallejo
Vallejo, California, 94589
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98664
Fox Chase Virtua Health Cancer Program at Virtua West Jersey
Voorhees Township, New Jersey, 08043
Ridgeview Medical Center
Waconia, Minnesota, 55387
Kaiser Permanente Medical Center - Walnut Creek
Walnut Creek, California, 94596
Central Dupage Cancer Center
Warrenville, Illinois, 60555
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Chester County Hospital
West Chester, Pennsylvania, 19380
Marshfield Clinic - Weston Center
Weston, Wisconsin, 54476
Michiana Hematology Oncology PC - La Porte
Westville, Indiana, 46391
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Willmar Cancer Center at Rice Memorial Hospital
Willmar, Minnesota, 56201
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157-1096
Minnesota Oncology - Woodbury
Woodbury, Minnesota, 55125
Kaiser Permanente Medical Cener - Woodland Hills
Woodland Hills, California, 91367
CCOP - Main Line Health
Wynnewood, Pennsylvania, 19096
Lankenau Cancer Center at Lankenau Hospital
Wynnewood, Pennsylvania, 19096
York Hospital's Oncology Treatment Center
York Village, Maine, 03909
Canada4 sites
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, K7L 5P9
St. Catharines General Hospital at Niagara Health System
Saint Catharines, Ontario, L2R 2Z7
Mount Sinai Hospital - Toronto
Toronto, Ontario, M5G 1X5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
About this study
Official title: Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue.
PURPOSE: This research study is studying biomarkers associated with fatigue in patients with early-stage breast cancer treated with metformin or placebo on NCIC-CTG-MA.32.
Read the detailed description
OBJECTIVES:
- To prepare, separate into components, and store the blood specimens at the NSABP Serum Bank at Baylor College of Medicine Breast Center for future DNA, RNA, and plasma analysis, and to analyze specific proinflammatory cytokines, genetic polymorphisms, and RNA expression arrays in collaborating laboratories at University of California, Los Angeles (UCLA).
- To examine the association between markers of inflammation and symptoms of fatigue among patients with and without exposure to metformin hydrochloride.
- To examine the relationship between single nucleotide polymorphism (SNPs) in the promoter regions of IL-1 and IL-6 and symptoms of fatigue with and without exposure to metformin hydrochloride.
- To examine RNA expression profiles in relationship to fatigue and compare the pattern of expression in patients with and without exposure to metformin hydrochloride.
- To determine the biological and behavioral predictors of fatigue in breast cancer patients in the five years post-randomization.
- To determine whether metformin is associated with reductions in inflammatory markers and corresponding decreases in fatigue. (Exploratory)
OUTLINE: This is a multicenter study.
Patients' serum and plasma, collected at baseline and at 6, 12, and 24 months after NCIC CTG MA.32 randomization, are analyzed for inflammatory markers, DNA polymorphisms, and RNA expression arrays by ELISA, TaqMan PCR, and RT-PCR.
Patients complete the Fatigue Symptom Inventory (symptoms associated with fatigue, sleep disturbance, depression, and endocrine therapy) at baseline and periodically during study.
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Being tested
- Metformin, Placebo
- Keywords
- fatigue, sleep disorders, depression, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer
- Medical subject headings
- Breast Neoplasms, Depression, Fatigue, Sleep Wake Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MetforminDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Metformin | 850 mg orally twice a day for 5 years Receives: Drug: Metformin | |
| Group 2: Placebo | One caplet orally twice a day for 5 years Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaire scores from patient reported outcome battery regarding fatigue, stress, sleep, depression, and general quality of life
Measured: Collected at baseline and 6, 12, 24, and 36 months from randomization
Questionnaire scores from patient reported comorbid conditions and behavioral risks
Measured: Collected at baseline and 6, 12, 24, and 36 months from randomization
Biological correlates of fatigue (medical and demographic characteristics of pts.)
Biological correlates (medical) will be collected at these timepoints. Standard demographics will be collected at baseline only.
Measured: Collected at baseline and 6, 12, 24, and 36 months from randomization
DNA polymorphisms
Measured: Collected at baseline
Changes in RNA gene expression
Measured: Collected at baseline and 6, 12, and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2011 (estimated)
- Study startJul 2011
- Primary completionSep 2016 (estimated)
- Study completionSep 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 394 participants (actual)
Sponsor and investigators
- Lead sponsor
- NSABP Foundation Inc
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Norman Wolmark, MD, Principal investigator, NSABP Foundation Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01286233
- Sponsor's protocol ID
- NSABP MA.32.F
- Other IDs
- NSABP-NCIC-CTG-MA.32.F
- Status last verified
- Sep 2015
- First submitted
- 27 Jan 2011
- Last updated
- 9 Sep 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
- ClinicalTrials.gov ID
- NCT01286233
- Acronym / sponsor ID
- NSABP MA.32.F
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Keywords
- fatigue, sleep disorders, depression, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 394 participants (actual)
- Lead sponsor
- NSABP Foundation IncResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Jul 2011
- Primary completion
- Sep 2016 (estimated)
- Study completion
- Sep 2016 (estimated)
- First posted
- 31 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Studying samples of blood in the laboratory from patients with breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue.
PURPOSE: This research study is studying biomarkers associated with fatigue in patients with early-stage breast cancer treated with metformin or placebo on NCIC-CTG-MA.32.
Detailed description
OBJECTIVES:
- To prepare, separate into components, and store the blood specimens at the NSABP Serum Bank at Baylor College of Medicine Breast Center for future DNA, RNA, and plasma analysis, and to analyze specific proinflammatory cytokines, genetic polymorphisms, and RNA expression arrays in collaborating laboratories at University of California, Los Angeles (UCLA).
- To examine the association between markers of inflammation and symptoms of fatigue among patients with and without exposure to metformin hydrochloride.
- To examine the relationship between single nucleotide polymorphism (SNPs) in the promoter regions of IL-1 and IL-6 and symptoms of fatigue with and without exposure to metformin hydrochloride.
- To examine RNA expression profiles in relationship to fatigue and compare the pattern of expression in patients with and without exposure to metformin hydrochloride.
- To determine the biological and behavioral predictors of fatigue in breast cancer patients in the five years post-randomization.
- To determine whether metformin is associated with reductions in inflammatory markers and corresponding decreases in fatigue. (Exploratory)
OUTLINE: This is a multicenter study.
Patients' serum and plasma, collected at baseline and at 6, 12, and 24 months after NCIC CTG MA.32 randomization, are analyzed for inflammatory markers, DNA polymorphisms, and RNA expression arrays by ELISA, TaqMan PCR, and RT-PCR.
Patients complete the Fatigue Symptom Inventory (symptoms associated with fatigue, sleep disturbance, depression, and endocrine therapy) at baseline and periodically during study.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Metformin | – | Drug: Metformin850 mg orally twice a day for 5 years |
| Group 2: Placebo | – | Drug: PlaceboOne caplet orally twice a day for 5 years |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with breast cancer who have been diagnosed and have undergone definitive surgical treatment for invasive breast cancer within the previous 12 months and who are eligible for randomization to NCIC MA.32.
Key inclusion criteria (7 listed)
- The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the MA.32.F Study before being enrolled.
- The patient must be female.
- The patient must reside in the United States or Canada.
- The patient must be English-speaking.
- The patient must be eligible for randomization in the MA.32 treatment trial. (Participation in the MA.32 QOL study is permitted but not required.)
Key exclusion criteria (2 listed)
- MA.32 study therapy has been initiated.
- Currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting MA.32 study therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metformin | Drug | Group 1: Metformin |
| Placebo | Drug | Group 2: Placebo |
Primary outcome
Questionnaire scores from patient reported outcome battery regarding fatigue, stress, sleep, depression, and general quality of life
Time frame: Collected at baseline and 6, 12, 24, and 36 months from randomization
Questionnaire scores from patient reported comorbid conditions and behavioral risks
Time frame: Collected at baseline and 6, 12, 24, and 36 months from randomization
Biological correlates of fatigue (medical and demographic characteristics of pts.)
Time frame: Collected at baseline and 6, 12, 24, and 36 months from randomization
Biological correlates (medical) will be collected at these timepoints. Standard demographics will be collected at baseline only.
DNA polymorphisms
Time frame: Collected at baseline
Changes in RNA gene expression
Time frame: Collected at baseline and 6, 12, and 24 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2015.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Norman Wolmark, MD principal investigator
NSABP Foundation Inc
256 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Depression, run by NSABP Foundation Inc at 256 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 256 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaire scores from patient reported outcome battery regarding fatigue, stress, sleep, depression, and general quality of life (time frame: Collected at baseline and 6, 12, 24, and 36 months from randomization). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2015.